HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

ofatumumab

an anti-CD20 MAb used as an antineoplastic agent; in phase 1-2 clinical trials
Also Known As:
GSK-1841157; GSKI841157; HUMAX-CD20 2F2; HUMAX-CD20, 2F2; HUMAX-CD20-2F2; arzerra; kesimpta
Networked: 357 relevant articles (46 outcomes, 114 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1. Robak, Tadeusz: 17 articles (01/2020 - 02/2008)
2. Lisby, Steen: 14 articles (02/2017 - 11/2011)
3. Jewell, Roxanne C: 12 articles (01/2017 - 04/2012)
4. Stilgenbauer, Stephan: 10 articles (01/2021 - 04/2010)
5. Grosicki, Sebastian: 10 articles (01/2020 - 05/2015)
6. Hillmen, Peter: 10 articles (01/2020 - 04/2010)
7. Montillo, Marco: 10 articles (01/2020 - 07/2014)
8. Kipps, Thomas J: 9 articles (01/2019 - 04/2010)
9. Häring, Dieter A: 8 articles (10/2022 - 01/2020)
10. Wierda, William G: 8 articles (01/2020 - 04/2010)

Related Diseases

1. B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
2. Neoplasms (Cancer)
3. Multiple Sclerosis
4. Relapsing-Remitting Multiple Sclerosis
5. Nephrotic Syndrome (Syndrome, Nephrotic)

Related Drugs and Biologics

1. Rituximab (Mabthera)
2. Monoclonal Antibodies
3. ibrutinib
4. Bendamustine Hydrochloride
5. Antibodies
6. ocrelizumab
7. teriflunomide
8. Alemtuzumab (Campath)
9. Prednisone (Sone)
10. Natalizumab (Tysabri)

Related Therapies and Procedures

1. Therapeutics
2. Stem Cell Transplantation
3. Salvage Therapy
4. Aftercare (After-Treatment)
5. Drug Therapy (Chemotherapy)